Tyverb in combination with AI: safety
Tyverb has a well-established safety profile1,2
Safety in the pivotal study EGF30008
The safety of Tyverb in combination with an aromatase inhibitor (AI) was evaluated in the pivotal phase III EGF30008 study. In this study, all patients of the combination group received letrozole.1
Tyverb in combination with an AI represents an effective treatment option in HER2+ hormone receptor-positive (HR+) metastatic breast cancer that could delay the need for chemotherapy in appropriate patients.1
Adapted from Johnston S, Pippen J Jr, Pivot X, et al. J Clin Oncol. 2009;27:5538–5546.
Adverse events in the HER2+ population of the pivotal EGF30008 study
Grade1/2 diarrhoea and rash were the most frequent adverse events in the HER2+ HR+ population.3
9% of patients experienced grade 3 diarrhoea.2 In the majority of cases (93%), diarrhoea resolved with no action. Where action was required, diarrhoea was effectively managed by dose reduction (2%) or temporary interruption (4%).3
Further information on the EGF30008 study can be found in the clinical evidence section.